Bio-Rad Laboratories A (BIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.62
- EPS estimate
- $1.75
- EPS surprise
- +49.92%
- Revenue surprise
- +4.33%
- Revenue
- $651.0M
- Revenue estimate
- $624.0M
- Reported
- Aug 4, 2026
Bio-Rad reported Q2 2026 results on August 4, 2026. EPS of $2.62 beat the $1.75 estimate by 49.92%. Revenue was $651.0 million, 4.33% above the $624.0 million estimate. Against Q2 2025, both were essentially flat: EPS edged up from $2.61 and revenue slipped from $651.6 million. EPS rebounded from $1.89 in Q1 2026, the lowest in the table.
Annual EPS has declined each year in the table, from $14.23 in 2022 to $11.77 in 2023, $10.31 in 2024 and $9.92 in 2025. The first half of 2026 totals $4.51, about 12% below the first half of 2025. Annual revenue has been steadier, between $2.57 billion and $2.80 billion in those four years. The EPS high was $4.94 in Q1 2022, and quarterly revenue peaked at $747.0 million in Q3 2021. Over the last 20 quarters, Bio-Rad beat EPS estimates 14 times and missed 6, including Q4 2025 and Q1 2026.
Q3 results arrived between October 26 and October 30 in each of the past five years, pointing to late October 2026 for the next report. It will show whether EPS holds near the Q2 level and how revenue compares with the $653.0 million reported for Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $1.75 | $2.62 | +49.92% | $651.0M | SEC |
| Q1 2026 | Apr 30, 2026 | $1.97 | $1.89 | −4.21% | $592.1M | SEC |
| Q4 2025 | Feb 12, 2026 | $2.71 | $2.51 | −7.31% | $693.2M | SEC |
| Q3 2025 | Oct 29, 2025 | $1.95 | $2.26 | +15.66% | $653.0M | SEC |
| Q2 2025 | Jul 31, 2025 | $1.73 | $2.61 | +50.52% | $651.6M | SEC |
| Q1 2025 | May 1, 2025 | $1.81 | $2.54 | +40.31% | $585.4M | SEC |
| Q4 2024 | Feb 13, 2025 | $2.87 | $2.90 | +1.10% | $667.5M | SEC |
| Q3 2024 | Oct 30, 2024 | $1.16 | $2.01 | +73.70% | $649.7M | SEC |
| Q2 2024 | Aug 1, 2024 | $2.01 | $3.11 | +54.38% | $638.5M | SEC |
| Q1 2024 | May 7, 2024 | $2.15 | $2.29 | +6.70% | $610.8M | SEC |
| Q4 2023 | Feb 15, 2024 | $2.82 | $3.10 | +10.00% | $681.2M | SEC |
| Q3 2023 | Oct 26, 2023 | $2.78 | $2.33 | −16.25% | $632.1M | SEC |
| Q2 2023 | Aug 3, 2023 | $2.68 | $3.00 | +11.98% | $681.1M | SEC |
| Q1 2023 | May 4, 2023 | $3.54 | $3.34 | −5.71% | $676.8M | SEC |
| Q4 2022 | Feb 16, 2023 | $3.45 | $3.31 | −4.01% | $730.3M | SEC |
| Q3 2022 | Oct 27, 2022 | $2.78 | $2.60 | −6.55% | $680.8M | — |
| Q2 2022 | Jul 28, 2022 | $2.80 | $3.38 | +20.77% | $691.1M | — |
| Q1 2022 | Apr 28, 2022 | $3.37 | $4.94 | +46.64% | $700.1M | — |
| Q4 2021 | Feb 10, 2022 | $2.85 | $3.21 | +12.60% | $732.8M | — |
| Q3 2021 | Oct 28, 2021 | $2.44 | $3.71 | +52.22% | $747.0M | — |
Quarterly revenue
Frequently asked questions
When did Bio-Rad Laboratories A (BIO) last report earnings?
Bio-Rad Laboratories A last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did BIO beat earnings estimates?
Yes. Bio-Rad Laboratories A reported EPS of $2.62 for Q2 2026 against a $1.75 estimate — a 49.92% beat.
How much revenue did BIO report last quarter?
Bio-Rad Laboratories A reported $651.0M in revenue for Q2 2026, against a consensus estimate of $624.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.